These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome. Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659 [TBL] [Abstract][Full Text] [Related]
6. Review article: the safety profile of tegaserod. Schoenfeld P Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852 [TBL] [Abstract][Full Text] [Related]
7. Tegaserod for constipation-predominant irritable bowel syndrome. Kale-Pradhan PB; Wilhelm SM Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916 [TBL] [Abstract][Full Text] [Related]
8. Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation. Müller-Lissner S; Holtmann G; Rueegg P; Weidinger G; Löffler H Aliment Pharmacol Ther; 2005 Jan; 21(1):11-20. PubMed ID: 15644040 [TBL] [Abstract][Full Text] [Related]
9. The effects of withdrawing tegaserod treatment in comparison with continuous treatment in irritable bowel syndrome patients with abdominal pain/discomfort, bloating and constipation: a clinical study. Bardhan KD; Forbes A; Marsden CL; Mason T; Short G Aliment Pharmacol Ther; 2004 Jul; 20(2):213-22. PubMed ID: 15233702 [TBL] [Abstract][Full Text] [Related]
10. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial. Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346 [TBL] [Abstract][Full Text] [Related]
11. A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Tack J; Müller-Lissner S; Bytzer P; Corinaldesi R; Chang L; Viegas A; Schnekenbuehl S; Dunger-Baldauf C; Rueegg P Gut; 2005 Dec; 54(12):1707-13. PubMed ID: 16020489 [TBL] [Abstract][Full Text] [Related]
12. Budget impact of tegaserod on a managed care organization formulary. Bloom MA; Barghout V; Kahler KH; Bentkover J; Kurth H; Gralnek IM; Spiegel BM Am J Manag Care; 2005 Apr; 11(1 Suppl):S27-34. PubMed ID: 15926761 [TBL] [Abstract][Full Text] [Related]
13. Tegaserod for the treatment of chronic constipation: a randomized, double-blind, placebo-controlled multinational study. Kamm MA; Müller-Lissner S; Talley NJ; Tack J; Boeckxstaens G; Minushkin ON; Kalinin A; Dzieniszewski J; Haeck P; Fordham F; Hugot-Cournez S; Nault B Am J Gastroenterol; 2005 Feb; 100(2):362-72. PubMed ID: 15667494 [TBL] [Abstract][Full Text] [Related]
14. Tegaserod for the treatment of constipation-predominant irritable bowel syndrome. Baker DE Rev Gastroenterol Disord; 2001; 1(4):187-98. PubMed ID: 12120185 [TBL] [Abstract][Full Text] [Related]
15. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Khoshoo V; Armstead C; Landry L Aliment Pharmacol Ther; 2006 Jan; 23(1):191-6. PubMed ID: 16393297 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation. Al-Judaibi B; Chande N; Gregor J Can J Clin Pharmacol; 2010; 17(1):e194-200. PubMed ID: 20410554 [TBL] [Abstract][Full Text] [Related]
17. Tegaserod in patients with irritable bowel syndrome. Schooff M; Stelter C Am Fam Physician; 2004 Dec; 70(11):2107-8. PubMed ID: 15606056 [No Abstract] [Full Text] [Related]
18. [A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of tegaserod in Chinese patients with constipation-predominant irritable bowel syndrome]. Tegaserod Clinical Research Group Zhonghua Nei Ke Za Zhi; 2003 Feb; 42(2):88-90. PubMed ID: 12783702 [TBL] [Abstract][Full Text] [Related]
19. Tegaserod treatment for IBS: a model of indirect costs. Smith DG; Barghout V; Kahler KH Am J Manag Care; 2005 Apr; 11(1 Suppl):S43-50. PubMed ID: 15926763 [TBL] [Abstract][Full Text] [Related]
20. A response to Farup and Bytzer. Tegaserod Nordic trial. Nyhlin H; Hunt R Scand J Gastroenterol; 2004 Aug; 39(8):803-4. PubMed ID: 15513374 [No Abstract] [Full Text] [Related] [Next] [New Search]